Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Stock Information for Black Diamond Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Black Diamond Therapeutics Inc.

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.